Ricardo awarded over 18.9million USD to deliver additional ABS/ESC retrofit kits to US Army
The United States Army has awarded Ricardo’s Defense business unit, located in Michigan, over 18.9million USD to deliver additional Antilock Brake System/Electronic Stability Control (ABS/ESC) retrofit kits to improve the safety of operation of the US Army’s High Mobility Multipurpose Wheeled Vehicle (HMMWV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005571/en/
Ricardo Awarded Over 18.9 million USD to Deliver Additional ABS/ESC Retrofit Kits to US Army (Photo: Business Wire)
In addition to those retrofit kits Ricardo has previously delivered, this contract award will improve safety on fielded vehicles in the US Army’s enduring HMMWV fleet. Additionally, more than 7,000 new production or recapitalized HMMWV vehicles have been delivered to the US Army with Ricardo’s integrated ABS/ESC technology following the Army’s mandate of the Ricardo system on all new production HMMWVs. In 2019, the Army provisioned Ricardo’s ABS/ESC retrofit kit into the national stock system for application of vehicles produced prior to 2019 that are slated to remain in the Army’s enduring fleet through 2040.
Chet Gryczan, President of Ricardo Defense said: “Ricardo is committed to providing our customers with mission critical, innovative, integrated solutions that deliver capability to the soldier. This award demonstrates that Ricardo can solve tough challenges for legacy systems that require a future-looking integrated solution. Consistent with our core values of sustainable, safe, and smart mobility, the successful deployment of Ricardo’s ABS/ESC safety critical system ensures the safety of soldiers and operators remain at the forefront of every training and operational mission. We are extremely proud to support the US Army’s objective ensuring that soldier safety remains a top priority throughout each mission.”
The Ricardo developed ABS/ESC retrofit system encompasses a complete solution integrated into the HMMWV architecture including antilock braking, electronic stability control, active rollover protection, traction control, and improved brake calipers, pads, and rotors. The Ricardo system additionally introduces a crashworthy steering column and a modern electronic network to the vehicle and leverages low-cost, proven components specifically designed for the arduous requirements of military application. From the beginning, Ricardo designed the system for ease of upgrade to the existing fleet to minimize HMMWV lifecycle cost to US taxpayers.
Ends
Ricardo Defense Inc, is the business entity within Ricardo plc that works on classified safety and defence contracts for the US DoD and it therefore operates as a separate entity governed by a Special Security Agreement (SSA). Ricardo Defense Inc provides solutions to meet the challenges faced by defence customers in the integration of complex and diverse systems specialising in taking innovative technologies from science to real-world deployment.
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
Ricardo Defense Inc, is the business entity within Ricardo plc that works on classified safety and defence contracts for the US DoD and it therefore operates as a separate entity governed by a Special Security Agreement (SSA). Ricardo Defense Inc provides solutions to meet the challenges faced by defence customers in the integration of complex and diverse systems specialising in taking innovative technologies from science to real-world deployment.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005571/en/
Contact information
Media contacts:
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
Kathryn Caulfield
Communications Manager
Ricardo Defense
Email: kathryn.caulfield@ricardodefense.com
Telephone: +1 (586) 899-7668
Cell: +1(248) 602-5159
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom